Portfolio

Our investment portfolio includes these selected examples. Original underwriting dates shown, with dollar amounts rounded to nearest million.

Current Investments

Acerus Pharmaceuticals

10.11.18
$11 million – Structured Credit

Beleodaq

06.06.18
$7.5 million – Royalty Acquisition

Besivance

04.02.13
$16 million – Royalty Acquisition

Best ABT

11.12.18
$5.8 million – Royalty Reorganization

BIOLASE

11.09.18
$15 million – Structured Credit

Biotricity

12.27.21
$12 million – Structured Credit

Cambia

07.31.14
$9.5 million – Royalty Acquisition

B&D Dental

12.10.13
$6.5 million – Structured Credit

Coflex

08.31.20
$4.4 million – Royalty Portfolio Acquisition

Enteris

08.27.19
$21.5 million - Company Purchase

Epica International

07.25.18
$14 million – Structured Credit

Eton Pharmaceuticals

11.14.19
$10 million – Structured Credit

Flowonix Medical

12.23.20
$10 million - Structured Credit

ForFivo (IntelGenx)

08.05.16
$6 million – Royalty Acquisition

4WEB Medical

06.03.19
$20 million - Structured Credit

Iluvien

12.18.20
$16.5 million – Royalty Acquisition

Keystone Dental

05.23.16
$20 million – Structured Credit

Kybella

08.31.20
$4.4 million – Royalty Portfolio Acquisition

MolecuLight

1.04.22
$10 million – Structured Credit

Narcan

11.07.16
$17.5 million – Royalty Acquisition

Sincerus Pharmaceuticals

3.19.21
$9 million - Structured Credit

Tissue Regeneration Therapeutics

06.12.13
$3.3 million – Royalty Acquisition

Trio Healthcare

10.22.20
$3.9 million - Royalty Acquisition

Trio Healthcare

7.01.21
$9.5 million - Structured Credit

Veru

03.05.18
$12 million – Synthetic Royalty Financing

Zalviso

08.31.20
$4.4 million - Royalty Portfolio Acquisition

Secured Royalty Financing for Pharmaceutical Product

Women's
Health
06.07.13
$3.0 million – Royalty Financing

Legacy Investments

Nautilus

12.05.12
$22.5 million – Structured Credit

InnoPran XL

05.14.13
$13 million – Acquisition & Sublicensing

Tribute

08.08.13
$14 million – Structured Credit

SynCardia

12.13.13
$10 million – Structured Credit & Synthetic Royalty Financing

Parnell #1

01.23.14
$25 million – Structured Credit

Response Genetics

07.30.14
$12 million – Structured Credit

ABT

10.10.14
$10 million – Structured Credit

PDI

10.13.14
$20 million – Structured Credit

Galil

12.10.14
$12.5 million – Structured Credit

Hooper Holmes

04.17.15
$5 million – Structured Credit

Nanosphere

05.14.15
$30 million – Structured Credit

Parnell #2

11.22.16
$20 million – Structured Credit

OraMetrix

12.15.16
$8.5 million – Structured Credit

Hooper Holmes / Provant

05.01.17
$8.5 million – Structured Credit

EyePoint Pharmaceuticals

03.28.18
$20 million – Structured Credit

Thermedx LLC

05.05.16
$3.5 million– Structured Credit

Solsys (f/k/a Soluble Systems)

10.26.17
$20 million – Structured Credit

Cheetah Medical

01.15.19
$20 million – Structured Credit

Aimmune Therapeutics

02.12.19
$5 million – Structured Credit

Tenex Health

07.01.16
$9 million – Structured Credit

Harrow Health

07.19.17
$21 million – Structured Credit

Misonix

9.27.19
$30 million – Structured Credit

DxTerity

04.06.15
$9.5 million – Structured Credit

CeloNova BioSciences

07.31.17
$25 million – Structured Credit

Harrow Health

05.05.16
$0.4 million – Note Financing